JPMorgan BetaBuilders MSCI U.S. REIT ETF (BATS: BBRE)

Latest news for JPMorgan BetaBuilders MSCI U.S. REIT ETF (BATS:BBRE)

Real Estate

Other

The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is a free-float adjusted market-cap weighted index designed to measure the performance of U.S. equity real estate investment trust (REIT) securities. The fund may invest up to 20% of its assets in exchange-traded futures to seek performance that corresponds to the underlying index.

Prologis Inc

Equinix, Inc.

Welltower Inc.

Simon Property Group Inc

Public Storage

Realty Income Corp.

Digital Realty Trust Inc.

Extra Space Storage Inc.

Iron Mountain Inc.

Vici Properties Inc

JPMorgan BetaBuilders MSCI US REIT ETF

JPMorgan BetaBuilders MSCI U.S. REIT ETF

WIIM

BLDR

Builders FirstSource shares are trading higher. The company appointed Peter Jackson as its next President and CEO and Pete Beckmann As CFO.

MBLY

Mobileye shares are trading higher after Intel reportedly said it does not have plans to divest a majority interest in the company.

− Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in Narcolepsy Type 1 Highlighting Impact on Daily Functioning Including Cognition and Sleep Quality
− Data from Long-Term Extension Study will also be Presented
− Phase 3 Trial of an Orexin Agonist for Narcolepsy Type 1 Now Enrolling Patients Globally
Takeda((<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;,%20url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&amp;,%20esheet=54124174&amp;,%20newsitemid=20240919392083&amp;,%20lan=en-US&amp;,%20anchor=TSE%3A4502%2FNYSE%3ATAK&amp;,%20index=1&amp;,%20NYSE:%3Ca%20class=">TAK</a>) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), being held September 24-27, 2024 in Seville, Spain. TAK-861 is an investigational oral orexin receptor 2 (OX2R) selective-agonist designed to address the orexin deficiency in NT1 by selectively stimulating the orexin receptor 2. TAK-861 has the potential to be the first treatment to address the underlying pathophysiology of NT1. Based on the positive Phase 2b trial results, Takeda has initiated the FirstLight Study, a global Phase 3 trial evaluating the efficacy and safety of TAK-861 in adults with NT1.

Biotech

News

General

Takeda To Present Additional Clinical Trial Study Data Highlighting The Impact Of Orexin Agonist TAK-861 On The Burden Of Narcolepsy At Sleep Europe 2024

PGNY

Progyny shares are trading lower after a client elected to exercise an option to terminate its services agreement with the company.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fastriatx.com%2F&amp;esheet=54124067&amp;newsitemid=20240919236987&amp;lan=en-US&amp;anchor=Astria+Therapeutics%2C+Inc.&amp;index=1&amp;md5=1b6ed34c07d2e6ec049db7d767adfac4">Astria Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present initial navenibart ALPHA-STAR data at the upcoming European Academy of Dermatology and Venereology (EADV) Congress in Amsterdam, the Netherlands on September 26, 2024.
Raffi Tachdjian, M.D., MPH, Associate Clinical Professor of Medicine and Pediatrics in the Division of Allergy and Clinical Immunology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA), will present a poster titled "ALPHA-STAR, a Phase 1b/2 Clinical Trial of Single and Multiple Doses of STAR-0215 in Patients with Hereditary Angioedema: Initial Safety and Efficacy Outcomes." The poster will be presented in e-poster showcase six on Thursday, September 26 at 4:20pm CEST.

ATXS

Astria Therapeutics To Present Initial Navenibart ALPHA-STAR Data At The Upcoming European Academy Of Dermatology And Venereology Congress

Guidance

CBRL

Cracker Barrel Old Country Store Sees FY25 Total Revenue Of $3.4B-$3.5B Vs. $3.45B Estimate

ALGS

Aligos Therapeutics Announces Results From Phase 2a HERALD  Study Showing ALG-055009 Dose Groups Met Primary Endpoint With Statistically Significant Reductions In Liver Fat At Week 12

ARQT

Arcutis Announces Publication Of Phase 3 Results For ZORYVE (Roflumilast) Cream 0.15% In JAMA Dermatology, Demonstrating Significant Efficacy And Safety In Treating Mild To Moderate Atopic Dermatitis In Adults And Children

Piper Sandler analyst Michael Lavery maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Overweight and raises the price target from $74 to $84.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on General Mills, Raises Price Target to $84

GLMD: 60% &#x7C; <a href="https://www.benzinga.com//node/40935862">Galmed Pharmaceuticals Plans To Broaden Its Drug Development Activities, Consisting Of Two Additional Programs Over The Next Two Years</a>
&nbsp;
EWTX: 42% &#x7C; <a href="https://www.benzinga.com//node/40935611">Edgewise Therapeutics Announced Top-line Data Of EDG-7500 From The Phase 1 Trial In Healthy Subjects And The Single-dose Arm Of Phase 2 CIRRUS-HCMtrial In Patients With Obstructive Obstructive Hypertrophic Cardiomyopathy</a>
&nbsp;
XCUR: 271% &#x7C; <a href="https://www.benzinga.com//node/40927738">Exicure shares are trading higher after the company announced it received an extension from the Nasdaq Hearings Panel.</a>

Movers

Trading Ideas

EWTX

GLMD

XCUR

Market-Moving News for September 19th

TD Cowen analyst Andrew Charles reiterates Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Hold and maintains $150 price target.

Reiteration

TD Cowen Reiterates Hold on Darden Restaurants, Maintains $150 Price Target

Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares came under pressure <a href="https://www.benzinga.com/tech/24/09/40930388/apple-iphone-16-pre-orders-show-possible-low-demand-one-sign-could-point-to-company-breaking-this-em">following commentary about demand immediately after pre-orders began </a>but a bullish analyst explained on Wednesday why the early trends should not be a cause for worry.
The Apple Analyst: Morgan Stanley analyst Erik Woodring has an Overweight rating and a $273 price target for Apple.
The Apple Thesis: iPhone 16 lead times have doubled from last Friday and have been longer internationally than in the U.S., but it is still tracking lower year-over-year, said Woodring in a note. As of Sept. 17, four days after preorders started:
<ul>
<li>The U.S. lead time is 14.4 days, up 100% from last Friday;</li>
<li>But lower than the 21.6-day average for all iPhone 15 models during the same period last year;</li>
<li>And 18-day average for all iPhone 14 models four days after preorders started in 2022.</li>
</ul>
Morgan Stanley&#8217;s tracking model going back to 2017 showed there is a directional, positive relationship between average lead times in the first two weeks after preorders began and the strength of iPhone shipments over the 12 months, Woodring said. &#8220;The longer the average lead time in the first two weeks after pre-orders begin, generally, the stronger the next 12-month shipments are for that specific iPhone model,&#8221; he said. 
That said, no strong correlation exists when comparing new iPhone model lead times in the first two weeks until the December quarter and total shipments over the next 12 months, the analyst said. &#8220;This is because lead times are influenced by both supply and demand, making iPhone lead times as a proxy this early in the cycle not yet truly informative,&#8221; he said.
See Also: <a href="https://www.benzinga.com/money/best-tech-stocks">Best AI Stocks Right Now</a>
According to the analyst, the shorter lead times this time around could be due to:
<ul>
<li>Apple directing the supply chain to build 5% more iPhone 16s in the second half of the calendar year 2024 than iPhone 15s during the comparable period in 2023;</li>
<li>The key reason for upgrading to the iPhone 16, <a href="https://www.benzinga.com/news/24/09/40780100/apple-intelligence-ready-iphone-16-with-faster-processor-dedicated-camera-button-announced-check-pri">Apple Intelligence features,</a> may not be available in the U.S. until October. In the U.K. it would be available only later this year, and the Chinese and Japanese customers get those only next year. This could be delaying upgrades, Woodring said.</li>
</ul>
The Apple Stock: Looking at stock implications, Woodring said at $216, Apple traded at a relatively full 29 times Morgan Stanley&#8217;s 2025 earnings per share estimate of $7.50. Any near-term outperformance from here would have to come from a growth acceleration/positive earnings revisions, he said. 
That said, the analyst noted that the December quarter iPhone builds have been revised lower by 3-6 million units over the last decade. Every one million iPhone build reduction equates to 4-cent earnings per downside, with Apple&#8217;s price/earnings multiple contracting by 1.5 times, on average, in the three months after an iPhone launch, he said.
The analyst sees downside support for the stock around $197, which translates to $7.30 per share in earnings per share and 27 times multiple. 
But most bulls see the fiscal year 2026 and the iPhone 17 as the bigger cycle and any estimate cuts or near-term stock underperformance will likely get bought, leading to just a short window of underperformance before investors turn their attention to the iPhone 17 and FY26 earnings power, he said.
In premarket trading, Apple shares climbed 1.62% at $224.27, according to <a href="https://benzinga.grsm.io/register174">Benzinga Pro data.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40914325/apple-stock-reaction-after-iphone-launch-sparks-portfolio-managers-reflection-i-may">Apple Stock Reaction After iPhone Launch Sparks Portfolio Manager&#8217;s Reflection: &#8216;I May Be Wrong In The Short Term But&#8230;Will Be Back In The Long Run&#8217;</a></li>
</ul>
Image via Unsplash

Analyst Color

Equities

Tech

AAPL

Apple Analyst Shrugs Off Lukewarm Early iPhone 16 Demand Trends: Here's Why Soft Preorder Data Hasn't Dented Morgan Stanley's Bullish Thesis

Enables Qualifying Customers to Use HSA (Health Savings Account) or FSA (Flex Savings Account) Funds to Purchase BODi Nutritional Supplements and Fitness Offerings
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fthebeachbodycompany.com%2F&amp;esheet=54123782&amp;newsitemid=20240919616045&amp;lan=en-US&amp;anchor=The+Beachbody+Company%2C+Inc.&amp;index=1&amp;md5=a68ffec7f8eedd2d6d2930e2cd127850">The Beachbody Company, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BODI#NYSE">BODI</a>) ("BODi"), a leading fitness and nutrition company, announced today a strategic partnership with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.truemed.com%2F&amp;esheet=54123782&amp;newsitemid=20240919616045&amp;lan=en-US&amp;anchor=Truemed&amp;index=2&amp;md5=acec2721783fbebd5219ef6637be2923">Truemed</a>, a leading healthcare payment provider that helps qualified customers spend their HSA/FSA funds on supplements, exercise and other lifestyle interventions that can help treat or prevent chronic disease. The partnership enables qualifying BODi customers to use their pre-tax HSA or FSA money to pay for supplement purchases from BODi's best-in-class product portfolio, including its Shakeology superfood nutrition shakes. By using pre-tax income for purchases, BODi customers can access their supplements at a significant discount.
To access the partnership, current and new BODi customers can take an online medical assessment with Truemed to determine if they qualify for a Letter of Medical Necessity (LMN). If approved, the LMN is valid on all supplement purchases for a year and allows customers to save up to 40% on BODi supplements, including both one-time and monthly subscription purchases.

The Beachbody Company, Inc. Class A Common Stock

BODI

BODi And Truemed Partner To Provide Pre-Tax Reimbursement For BODi Health And Fitness Supplements

AEMD

Aethlon Receives Ethics Committee Approval For Hemopurifier Cancer Trial In India, Targeting Patients With Solid Tumors Unresponsive To Anti-PD-1 Therapy

Piper Sandler analyst Patrick Moley maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Overweight and raises the price target from $23 to $27.

HOOD

Piper Sandler Maintains Overweight on Robinhood Markets, Raises Price Target to $27

<a href="https://www.globenewswire.com/Tracker?data=IOZSQF7l2NlW9dojiDWx9HMQptoABpF2Il4ywCXA5XTPitneEGZNU0z2MWDTAUvxuelopl_woOJhmiPtw5Rn-w==">CorMedix Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced that it has entered into a new commercial supply contract with a top-tier mid-sized dialysis operator for the supply of DefenCath&#xAE; (taurolidine and heparin) to dialysis clinics in the US. This new agreement will provide access to DefenCath for adult patients with kidney failure receiving hemodialysis through a central venous catheter at more than 250 outpatient dialysis clinics located across the United States. &nbsp;
CorMedix received NDA approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD) on November 15, 2023, and began commercialization of the product in the inpatient setting on April 15, 2024. Outpatient reimbursement of DefenCath from the Center for Medicare &amp; Medicaid Services (CMS) took effect on July 1st, and CorMedix subsequently commenced the shipment of orders to outpatient dialysis facilities in July. CorMedix anticipates shipments for DefenCath under this agreement to begin in the beginning of the fourth quarter.

CRMD

CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States

AIM ImmunoTech Announces Prelim. Data From Phase 1b/2 Study Of Ampligen And Imfinzi; Says 'Preliminary finding of stable disease in two out of three patients at 6 months in the first subject cohort'

AMZN

NTAP

NetApp Signs Strategic Collaboration Agreement With AWS To Enhance Cloud-Based Data Services, Accelerate Generative AI Efforts, And Drive CloudOps Value

Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) reported quarterly earnings of $0.98 per share which missed the analyst consensus estimate of $1.10 by 10.91 percent. This is a 45.25 percent decrease over earnings of $1.79 per share from the same period last year. The company reported quarterly sales of $894.39 million which missed the analyst consensus estimate of $897.22 million by 0.32 percent. This is a 6.89 percent increase over sales of $836.73 million the same period last year.

Earnings

Earnings Misses

Cracker Barrel Old Q4 Adj $0.98 Misses $1.10 Estimate, Sales $894.39M Miss $897.22M Estimate

EVAX

Evaxion Announces An Update Of Its EDEN AI Prediction Model, Featuring A Novel Toxin Antigen Predictor

Portfolio Implications Of Powell's 'Whatever It Takes' Moment

Equity REITs see Q2 share repurchases more than double

Real estate stocks surge in August, set to rebound after underperformance

Patience Needed In The AI Buildout

Construction Spending Squeaks To Record, Residential Construction Tries To Dig Out Of Slump

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

JPMorgan BetaBuilders MSCI U.S. REIT ETF

News

Latest news for JPMorgan BetaBuilders MSCI U.S. REIT ETF (BATS:BBRE)